moa glp 1 Mechanism of action of GLP-1 [25] The Road towards Triple Agonists:

doi:10.1159/000450702 96. Pinheiro, J., Bates, D., DebRoy, S., Sarkar, D., Heisterkamp, S., Willigen, B., & Ranke, J

The duration of action is also individual and depends on many factors

Weeks Tirzepatide dose Notes 14 2.5 mg Initiation only (not for glucose/weight effect) 58 5 mg First maintenance option 912 7.5 mg Increase as tolerated 1316 10 mg Maintenance option 1720 12.5 mg Increase as tolerated 21+ 15 mg (max) Maximum maintenance dose These steps follow the Mounjaro FDA label and Zepbound FDA label

The regulatory green light was based on a Phase III trial that showed Rystiggo led to significant improvements in symptoms related to breathing, talking, swallowing and rising from a chair

RAMEL, C